Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA 4324 (miR-4324) is a small non-coding RNA belonging to the microRNA (miRNA) family that functions as a post-transcriptional regulator of gene expression, primarily by binding to complementary sequences in target mRNA transcripts, leading to their degradation or translational repression. miR-4324 is downregulated in several human cancers, including esophageal squamous-cell carcinoma and colorectal cancer[1][2]. In ESCC, decreased miR-4324 expression is associated with increased invasion, migration, and epithelial-to-mesenchymal transition (EMT), largely via its direct targeting and downregulation of focal adhesion kinase (FAK)[1]. In colorectal cancer, miR-4324 directly targets and suppresses homeobox B2 (HOXB2), inhibiting cell proliferation, migration, and invasion[2]. Its reduced expression in tumors and its impact on cancer cell behavior suggest a tumor suppressor role and potential utility as a prognostic biomarker[1][2]. At this time, miR-4324 itself is not considered a direct therapeutic target analogous to protein receptors, enzymes, or transporters, and no drugs are known to directly target or modulate miR-4324.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA 4324 (miR-4324).